Detalhe da pesquisa
1.
RRx-001, A novel dinitroazetidine radiosensitizer.
Invest New Drugs
; 34(3): 371-7, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26841903
2.
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.
Lancet Oncol
; 16(9): 1133-1142, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26296952
3.
From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria.
Malar J
; 14: 218, 2015 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26017006
4.
Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy.
Biochem Biophys Res Commun
; 447(3): 537-42, 2014 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-24735538
5.
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
Drug Metab Dispos
; 40(9): 1810-6, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22699395
6.
The Touchstone Process: an ongoing critical evaluation of reiki in the scientific literature.
Holist Nurs Pract
; 24(5): 260-76, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20706088
7.
Light-fluorous safety-catch arylgermanes - exceptionally robust, photochemically activated precursors for biaryl synthesis by Pd(0) catalysed cross-coupling.
Chem Commun (Camb)
; (28): 2926-8, 2007 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-17622433
8.
The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.
Clin Epigenetics
; 9: 4, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28149332
9.
Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors.
Oncotarget
; 8(60): 102511-102520, 2017 Nov 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-29254266
10.
No patient left behind: The promise of immune priming with epigenetic agents.
Oncoimmunology
; 6(10): e1315486, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29123948
11.
RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.
Expert Opin Investig Drugs
; 26(1): 109-119, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27935336
12.
RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors.
Clin Epigenetics
; 8: 53, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27175220
13.
Pulmonary Tumor Thrombotic Microangiopathy: A New Paraneoplastic Syndrome?
Case Rep Oncol
; 9(1): 246-8, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27239179
14.
The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis.
Case Rep Oncol
; 9(1): 68-75, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26933422
15.
Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy.
Oncotarget
; 7(8): 9041-5, 2016 Feb 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-26814434
16.
A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?
Med Oncol
; 33(7): 63, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27229330
17.
RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells.
Discov Med
; 21(116): 251-65, 2016 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27232511
18.
Rockets, radiosensitizers, and RRx-001: an origin story part I.
Discov Med
; 21(115): 173-80, 2016 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27115167
19.
Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.
Respir Med Case Rep
; 18: 62-5, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27330954
20.
RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report.
Case Rep Oncol
; 9(1): 45-50, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26933418